A Long-term Follow-up Study of Patients Who Received MB-105
NCT ID: NCT07340814
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
40 participants
OBSERVATIONAL
2026-02-27
2040-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Follow-up Study for Patients Previously Treated With JCAR015
NCT02813252
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
NCT02711852
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT07107204
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
NCT00718159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Observation
All patients who previously received MB-105 on another study
MB-105
This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MB-105
This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
March Biosciences Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MB-105-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.